Pharmaceuticals - Chile

Chile

The Pharmaceuticals market in Chile is projected to generate a revenue of US$2,446.00m in 2024.
Among the various markets, Oncology Drugs is anticipated to be the largest, with a projected market volume of US$471.90m in the same year.
The industry is expected to witness a steady annual growth rate of 6.24% from 2024 to 2028, resulting in a market volume of US$3,116.00m by 2028.
However, in a global context, United States is expected to generate the highest revenue, reaching US$636.90bn in 2024.
Chile has seen a surge in investment and research in the pharmaceutical sector, positioning the country as a key player in the Latin American market.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market in Chile has been developing at a steady pace over the years. Chile is one of the largest pharmaceutical markets in Latin America, and the growth of the industry is driven by several factors.

Customer preferences: Chilean consumers have shown a growing preference for generic drugs over branded drugs. This is due to the lower cost of generic drugs, which are often more affordable than their branded counterparts. Additionally, consumers are becoming more health-conscious and are seeking out drugs that are more effective in treating their health conditions.

Trends in the market: The pharmaceutical industry in Chile is expected to continue to grow over the next few years. The government has implemented policies that promote the use of generic drugs, which has led to increased competition among pharmaceutical companies. Additionally, the aging population in Chile has created a growing demand for drugs that treat chronic diseases such as diabetes and hypertension.

Local special circumstances: One of the unique aspects of the pharmaceutical industry in Chile is the role of the government in regulating drug prices. The government has implemented a system of price controls to ensure that drugs are affordable for all Chilean citizens. This has led to lower profit margins for pharmaceutical companies, but it has also made drugs more accessible to the general public.

Underlying macroeconomic factors: The Chilean economy has been stable over the past few years, which has contributed to the growth of the pharmaceutical industry. Additionally, the government has implemented policies that promote investment in the healthcare sector, which has led to increased investment in the pharmaceutical industry. Finally, the growing aging population in Chile has created a growing demand for drugs that treat chronic diseases, which has contributed to the growth of the industry.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.